When planning for tumor therapy, by targeting tumor cells by anti-CD276 therapy, underscoring CD276 expression by immunohistochemistry should take the seeming discrepancies between total CD276 protein in the cell versus on the cell surface into account. The gene discussed is CD276; the disease is neoplasm.